Landscapes / Oncology
Non-small cell lung cancer drug landscape
149 drugs in 487 active trials · Phase 3 and later · updated 16 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs149
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
ALK/ROS1 inhibitor |
Pfizer · Public PFE |
On the market | 31 Dec 2026Phase 3 trial completes | ||
| Next date | 31 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | NSCLC, Advanced Malignancies and 3 more | ||||
| Open drug page | |||||
TROP2-targeted antibody-drug conjugate |
Daiichi Sankyo +1 · Public AZN |
On the market | 11 Jan 2027Phase 3 trial completes | ||
| Next date | 11 Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | Triple Negative Breast Cancer, Hormone Receptor Positive Breast Cancer and 15 more | ||||
| Open drug page | |||||
EGFR inhibitor (third generation) |
AstraZeneca · Public AZN |
On the market | 11 Jan 2027Phase 3 trial completes | ||
| Next date | 11 Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | Carcinoma, Lung Cancer and 3 more | ||||
| Open drug page | |||||
Kinase inhibitor |
On the market | 30 Jul 2027Phase 4 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 30 Jul 2027 · Phase 4 trial completes | ||||
| Also tested for | Thyroid Cancer, Solid Tumor Malignancies and 1 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Pfizer · Public PFE |
On the market | 21 Mar 2028Phase 4 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 21 Mar 2028 · Phase 4 trial completes | ||||
| Also tested for | NSCLC, ALCL and 1 more | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
On the market | 11 Jun 2029Phase 1/2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 11 Jun 2029 · Phase 1/2 trial completes | ||||
| Also tested for | Melanoma, Solid Tumor and 3 more | ||||
| Open drug page | |||||
RET inhibitor |
Eli Lilly · Public LLY |
On the market | Oct 2029Phase 4 trial completes | ||
| Next date | Oct 2029 · Phase 4 trial completes | ||||
| Also tested for | Medullary Thyroid Cancer, Colon Cancer and 2 more | ||||
| Open drug page | |||||
Kinase inhibitor |
On the market | 28 Dec 2032Phase 4 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 28 Dec 2032 · Phase 4 trial completes | ||||
| Also tested for | Melanoma, Solid Tumor and 2 more | ||||
| Open drug page | |||||
Afatinibnot checked |
Kinase inhibitor |
Boehringer Ingelheim · Private |
Approved | — | |
| How it works | Blocks a kinase | ||||
| Open drug page | |||||
Brigatinibnot checked |
Kinase inhibitor |
Approved | — | ||
| How it works | Blocks a kinase | ||||
| Also tested for | ALK-positive Advanced NSCLC, ALK+ Advanced NSCLC | ||||
| Open drug page | |||||
Dacomitinibnot checked |
Tyrosine kinase inhibitor |
Pfizer · Public PFE |
Approved | — | |
| How it works | Blocks a kinase | ||||
| Open drug page | |||||
Docetaxelnot checked |
Microtubule inhibitor |
Approved | — | ||
| How it works | Taxane chemotherapy | ||||
| Also tested for | Carcinoma, Non Small Cell Lung | ||||
| Open drug page | |||||
ALK inhibitor |
Roche · Public ROG.SW |
Phase 3 | 30 Nov 2026soonPhase 2 trial completes | ||
| Next date | 30 Nov 2026 · Phase 2 trial completes | ||||
| Open drug page | |||||
Programmed death receptor-1 blocking antibody |
Roche · Public ROG.SW |
Phase 3 | 30 Nov 2026soonPhase 2 trial completes | ||
| How it works | Releases a brake on the immune system (PD-1 or PD-L1) so it attacks cancer cells | ||||
| Next date | 30 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Colorectal Cancer, Advanced Solid Tumors and 11 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Roche · Public ROG.SW |
Phase 2/3 | 30 Nov 2026soonPhase 2 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 30 Nov 2026 · Phase 2 trial completes | ||||
| Open drug page | |||||
KRAS G12C inhibitor |
Roche · Public ROG.SW |
Phase 3 | 30 Nov 2026soonPhase 2 trial completes | ||
| Next date | 30 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | KRAS G12C Lung Cancer, Colorectal Cancer and 1 more | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Roche · Public ROG.SW |
Phase 3 | 30 Nov 2026soonPhase 2 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 30 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Breast Cancer, Cholangiocarcinoma and 13 more | ||||
| Open drug page | |||||
EGFR-targeted antibody-drug conjugate |
CSPC · Public 1093.HK |
Phase 3 | 30 Nov 2026soonPhase 2 trial completes | ||
| Next date | 30 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | NSCLC | ||||
| Open drug page | |||||
PD-1/IL-2 bispecific fusion protein |
Innovent +1 · Public 1801.HK |
Phase 3 | 30 Nov 2026soonPhase 2 trial completes | ||
| Next date | 30 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Melanoma, Colorectal Cancer and 3 more | ||||
| Open drug page | |||||
BRAF inhibitor |
Roche · Public ROG.SW |
Phase 2/3 | 30 Nov 2026soonPhase 2 trial completes | ||
| Next date | 30 Nov 2026 · Phase 2 trial completes | ||||
| Open drug page | |||||
EGFR inhibitor |
Phase 3 | Nov 2026soonPhase 2 trial completes | |||
| Next date | Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | EGFR Mutation, Metastatic Lung Cancer and 1 more | ||||
| Open drug page | |||||
TROP2-targeted antibody-drug conjugate |
Kelun-Biotech +1 · Public 6990.HK · MRK |
Phase 3 | Nov 2026soonPhase 3 trial completes | ||
| Next date | Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | NSCLC, Lung Neoplasm Malignant and 5 more | ||||
| Open drug page | |||||
— |
Phase 3 | Nov 2026soonPhase 2 trial completes | |||
| Next date | Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Breast Cancer, Locally Advanced or Metastatic Solid Tumors and 5 more | ||||
| Open drug page | |||||
HER2 inhibitor |
Boehringer Ingelheim · Private |
Phase 3 | 10 Dec 2026soonPhase 3 trial completes | ||
| Next date | 10 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Neoplasm Metastasis | ||||
| Open drug page | |||||
Pembrolizumab biosimilar candidate |
Amgen · Public AMGN |
Phase 3 | 14 Dec 2026soonPhase 3 trial completes | ||
| Next date | 14 Dec 2026 · Phase 3 trial completes | ||||
| Open drug page | |||||
PD-1 antibody |
Merck & Co. · Public MRK |
Phase 3 | 15 Dec 2026soonPhase 1/2 trial completes | ||
| Next date | 15 Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Breast Cancer, Ovarian Cancer and 93 more | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
CSPC · Public 1093.HK |
Phase 3 | 25 Dec 2026Phase 2 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 25 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | C-Met Exon 14 Mutation, Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression | ||||
| Open drug page | |||||
Docetaxel, albumin-bound (chemotherapy) |
CSPC +1 · Public 1093.HK |
Phase 2/3 | 25 Dec 2026Phase 2 trial completes | ||
| Next date | 25 Dec 2026 · Phase 2 trial completes | ||||
| Open drug page | |||||
PD-L1 antibody |
Hengrui · Public 600276.SS |
Phase 3 | Dec 2026Phase 1/2 trial completes | ||
| Next date | Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | NSCLC | ||||
| Open drug page | |||||
Kinase inhibitor |
Pfizer · Public PFE |
Phase 3 | 31 Dec 2026Phase 3 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 31 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Advanced Malignancies, NSCLC and 3 more | ||||
| Open drug page | |||||
Vascular endothelial growth factor inhibitor |
Phase 3 | Dec 2026Phase 3 trial completes | |||
| How it works | Blocks VEGF | ||||
| Next date | Dec 2026 · Phase 3 trial completes | ||||
| Open drug page | |||||
HER2-targeted antibody-drug conjugate |
Phase 3 | Dec 2026Phase 1/2 trial completes | |||
| Next date | Dec 2026 · Phase 1/2 trial completes | ||||
| Open drug page | |||||
TLR7/8 agonist |
Phase 2/3 | Dec 2026Phase 2 trial completes | |||
| Next date | Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | NSCLC, Stage 4 NSCLC | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 3 | Dec 2026Phase 1/2 trial completes | |||
| How it works | An antibody | ||||
| Next date | Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Solid Tumors, Renal Cell Carcinoma and 1 more | ||||
| Open drug page | |||||
EGFR inhibitor (third generation) |
Allist Pharmaceuticals +1 |
Phase 3 | Dec 2026Phase 3 trial completes | ||
| Next date | Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | EGFR Exon 20 Mutations, NSCLC and 8 more | ||||
| Open drug page | |||||
CTLA-4 antibody |
OncoC4 +1 · Public BNTX |
Phase 3 | 31 Dec 2026Phase 1/2 trial completes | ||
| How it works | A cancer drug that hits three targets | ||||
| Next date | 31 Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Metastatic Melanoma and 16 more | ||||
| Open drug page | |||||
EGFR/HER3 bispecific antibody-drug conjugate |
Sichuan Baili (Biokin, SystImmune) +1 · Public BMY |
Phase 3 | Dec 2026Phase 2 trial completes | ||
| Next date | Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Nasopharyngeal Carcinoma, Esophageal Cancer and 9 more | ||||
| Open drug page | |||||
Pembrolizumab biosimilar candidate |
Phase 3 | Dec 2026Phase 3 trial completes | |||
| Next date | Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | NSCLC, Gastric Cancer (GC) and 3 more | ||||
| Open drug page | |||||
HER3-targeted antibody-drug conjugate |
Hengrui · Public 600276.SS |
Phase 3 | Dec 2026Phase 3 trial completes | ||
| Next date | Dec 2026 · Phase 3 trial completes | ||||
| Open drug page | |||||
— |
Phase 3 | Dec 2026Phase 1/2 trial completes | |||
| Next date | Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Squamous Cell Carcinoma of Lung | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Phase 3 | 31 Dec 2026Phase 1/2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 31 Dec 2026 · Phase 1/2 trial completes | ||||
| Open drug page | |||||
PD-L1 antibody |
AstraZeneca · Public AZN |
Phase 3 | 8 Jan 2027Phase 3 trial completes | ||
| Next date | 8 Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | NSCLC, Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer and 20 more | ||||
| Open drug page | |||||
Monoclonal antibody |
AstraZeneca · Public AZN |
Phase 3 | 8 Jan 2027Phase 3 trial completes | ||
| How it works | An antibody | ||||
| Next date | 8 Jan 2027 · Phase 3 trial completes | ||||
| Open drug page | |||||
Monoclonal antibody |
AstraZeneca · Public AZN |
Phase 3 | 8 Jan 2027Phase 3 trial completes | ||
| How it works | An antibody | ||||
| Next date | 8 Jan 2027 · Phase 3 trial completes | ||||
| Open drug page | |||||
TROP2-targeted antibody-drug conjugate |
Gilead (Kite) · Public GILD |
Phase 3 | 12 Jan 2027Phase 3 trial completes | ||
| Next date | 12 Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | Lung Cancer | ||||
| Open drug page | |||||
MET inhibitor |
HUTCHMED +1 · Public AZN |
Phase 3 | 18 Jan 2027Phase 2 trial completes | ||
| Next date | 18 Jan 2027 · Phase 2 trial completes | ||||
| Also tested for | Carcinoma, Lung Cancer | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 3 | 31 Jan 2027Phase 1/2 trial completes | |||
| How it works | An antibody | ||||
| Next date | 31 Jan 2027 · Phase 1/2 trial completes | ||||
| Open drug page | |||||
PD-1/VEGF bispecific antibody |
Akeso +1 · Public 9926.HK · SMMT |
Phase 3 | Jan 2027Phase 1/2 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | Jan 2027 · Phase 1/2 trial completes | ||||
| Also tested for | NSCLC, Advanced Solid Tumors and 8 more | ||||
| Open drug page | |||||
Programmed death receptor-1 blocking antibody |
Bristol Myers Squibb · Public BMY |
Phase 3 | 5 Feb 2027Phase 2 trial completes | ||
| How it works | Releases a brake on the immune system (PD-1 or PD-L1) so it attacks cancer cells | ||||
| Next date | 5 Feb 2027 · Phase 2 trial completes | ||||
| Also tested for | Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma and 8 more | ||||
| Open drug page | |||||
ROS1/TRK/ALK inhibitor |
Bristol Myers Squibb · Public BMY |
Phase 3 | 16 Feb 2027Phase 3 trial completes | ||
| Next date | 16 Feb 2027 · Phase 3 trial completes | ||||
| Open drug page | |||||
— |
Phase 3 | Feb 2027Phase 3 trial completes | |||
| Next date | Feb 2027 · Phase 3 trial completes | ||||
| Open drug page | |||||
EGFR antibody |
Phase 3 | 26 Mar 2027Phase 3 trial completes | |||
| Next date | 26 Mar 2027 · Phase 3 trial completes | ||||
| Also tested for | Harboring EGFR Common Mutation, Locally Advanced or Metastatic Non-squamous NSCLC and 2 more | ||||
| Open drug page | |||||
— |
Phase 3 | Mar 2027Phase 1/2 trial completes | |||
| Next date | Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | NSCLC, Solid Tumor and 3 more | ||||
| Open drug page | |||||
— |
Phase 3 | Mar 2027Phase 1/2 trial completes | |||
| Next date | Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | KRAS P.G12C, Colorectal Cancer and 1 more | ||||
| Open drug page | |||||
PD-1 antibody |
Phase 3 | 31 Mar 2027Phase 1/2 trial completes | |||
| Next date | 31 Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Pancreatic Ductal Adenocarcinoma, Metastatic Hepatocellular Carcinoma and 3 more | ||||
| Open drug page | |||||
— |
Henlius · Public 2696.HK |
Phase 3 | 9 Apr 2027Phase 3 trial completes | ||
| Next date | 9 Apr 2027 · Phase 3 trial completes | ||||
| Also tested for | Melanoma, Renal Cell Carcinoma | ||||
| Open drug page | |||||
KRAS G12D inhibitor |
GenFleet Therapeutics +1 |
Phase 3 | 30 Apr 2027Phase 2 trial completes | ||
| Next date | 30 Apr 2027 · Phase 2 trial completes | ||||
| Also tested for | Pancreatic Ductal Adenocarcinoma, Colorectal Cancer and 3 more | ||||
| Open drug page | |||||
— |
Phase 2/3 | 30 Apr 2027Phase 1 trial completes | |||
| Next date | 30 Apr 2027 · Phase 1 trial completes | ||||
| Also tested for | Colorectal Cancer, Solid Tumor and 3 more | ||||
| Open drug page | |||||
PD-1 antibody |
Regeneron · Public REGN |
Phase 2/3 | Apr 2027Phase 1/2 trial completes | ||
| Next date | Apr 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma and 1 more | ||||
| Open drug page | |||||
— |
Eli Lilly · Public LLY |
Phase 3 | Apr 2027Phase 1/2 trial completes | ||
| Next date | Apr 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Colorectal Neoplasms, Endometrial Neoplasms and 4 more | ||||
| Open drug page | |||||
EGFR inhibitor (exon 20 insertion mutations) |
Taiho +1 |
Phase 3 | 27 May 2027Phase 3 trial completes | ||
| Next date | 27 May 2027 · Phase 3 trial completes | ||||
| Also tested for | EGFR Exon 20 Mutation, Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations and 9 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Daiichi Sankyo +1 · Public AZN |
Phase 3 | 28 May 2027Phase 1/2 trial completes | ||
| How it works | An antibody | ||||
| Next date | 28 May 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Breast Cancer, Ovarian Cancer and 10 more | ||||
| Open drug page | |||||
CD44v9-targeted antibody-drug conjugate |
Phase 2/3 | 30 May 2027Phase 1/2 trial completes | |||
| Next date | 30 May 2027 · Phase 1/2 trial completes | ||||
| Open drug page | |||||
RAS inhibitor (active RAS, several mutations) |
Phase 3 | 31 May 2027Phase 1/2 trial completes | |||
| Next date | 31 May 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Colorectal Cancer (CRC), Advanced Solid Tumors and 20 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Phase 3 | 31 May 2027Phase 2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 31 May 2027 · Phase 2 trial completes | ||||
| Open drug page | |||||
PD-1 antibody |
Henlius · Public 2696.HK |
Phase 2/3 | 18 Jun 2027Phase 2 trial completes | ||
| Next date | 18 Jun 2027 · Phase 2 trial completes | ||||
| Also tested for | Solid Tumor Cancer, Small Cell Lung Cancer and 1 more | ||||
| Open drug page | |||||
Vascular endothelial growth factor inhibitor |
Roche · Public ROG.SW |
Phase 2/3 | 30 Jun 2027Phase 2/3 trial completes | ||
| How it works | Blocks VEGF | ||||
| Next date | 30 Jun 2027 · Phase 2/3 trial completes | ||||
| Also tested for | Colorectal Cancer, Advanced Solid Tumors | ||||
| Open drug page | |||||
— |
Phase 3 | 30 Jun 2027Phase 3 trial completes | |||
| Next date | 30 Jun 2027 · Phase 3 trial completes | ||||
| Also tested for | Untreated With Systemic Therapy | ||||
| Open drug page | |||||
KRAS G12C inhibitor |
Amgen · Public AMGN |
Phase 3 | 30 Jun 2027Phase 3 trial completes | ||
| Next date | 30 Jun 2027 · Phase 3 trial completes | ||||
| Also tested for | KRAS Activating Mutation, Thoracic Tumors | ||||
| Open drug page | |||||
Soluble LAG-3 protein (immune activator) |
Phase 3 | Jun 2027Phase 3 trial completes | |||
| Next date | Jun 2027 · Phase 3 trial completes | ||||
| Open drug page | |||||
KRAS G12D inhibitor |
Phase 3 | Jun 2027Phase 1/2 trial completes | |||
| Next date | Jun 2027 · Phase 1/2 trial completes | ||||
| Also tested for | NSCLC, Colorectal Cancer (CRC) and 16 more | ||||
| Open drug page | |||||
PD-L1/4-1BB bispecific antibody |
Phase 3 | 30 Jul 2027Phase 3 trial completes | |||
| Next date | 30 Jul 2027 · Phase 3 trial completes | ||||
| Also tested for | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | ||||
| Open drug page | |||||
Multi-specific immunoglobulin |
AstraZeneca · Public AZN |
Phase 3 | 30 Jul 2027Phase 2 trial completes | ||
| How it works | An antibody built to latch onto two or more targets at once | ||||
| Next date | 30 Jul 2027 · Phase 2 trial completes | ||||
| Open drug page | |||||
Telomere-targeting nucleotide |
Phase 3 | 31 Jul 2027Phase 3 trial completes | |||
| Next date | 31 Jul 2027 · Phase 3 trial completes | ||||
| Open drug page | |||||
PD-1/VEGF bispecific antibody |
Sinocelltech · Public 688520.SS |
Phase 3 | Jul 2027Phase 3 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | Jul 2027 · Phase 3 trial completes | ||||
| Open drug page | |||||
— |
Phase 3 | 31 Aug 2027Phase 3 trial completes | |||
| Next date | 31 Aug 2027 · Phase 3 trial completes | ||||
| Also tested for | Lung Cancer | ||||
| Open drug page | |||||
HER3-targeted antibody-drug conjugate |
Daiichi Sankyo +1 · Public MRK |
Phase 3 | 1 Sep 2027Phase 2 trial completes | ||
| Next date | 1 Sep 2027 · Phase 2 trial completes | ||||
| Also tested for | EGFR L858R, EGFR Exon 19 Deletion and 14 more | ||||
| Open drug page | |||||
LAG-3 antibody |
Regeneron · Public REGN |
Phase 2/3 | 28 Sep 2027Phase 2/3 trial completes | ||
| Next date | 28 Sep 2027 · Phase 2/3 trial completes | ||||
| Also tested for | Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma | ||||
| Open drug page | |||||
PD-1/TIGIT bispecific antibody |
AstraZeneca · Public AZN |
Phase 3 | 29 Sep 2027Phase 1/2 trial completes | ||
| Next date | 29 Sep 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Breast Cancer, Biliary Tract Carcinoma and 10 more | ||||
| Open drug page | |||||
PD-1 antibody |
CSPC · Public 1093.HK |
Phase 3 | 30 Sep 2027Phase 3 trial completes | ||
| Next date | 30 Sep 2027 · Phase 3 trial completes | ||||
| Open drug page | |||||
HER2/EGFR inhibitor |
Phase 3 | 28 Oct 2027Phase 3 trial completes | |||
| Next date | 28 Oct 2027 · Phase 3 trial completes | ||||
| Also tested for | EGFR Mutation, HER2 Mutation | ||||
| Open drug page | |||||
MET inhibitor unconfirmed |
Phase 3 | 31 Oct 2027Phase 3 trial completes | |||
| Next date | 31 Oct 2027 · Phase 3 trial completes | ||||
| Also tested for | EGFR Activating Mutation, MET Positive | ||||
| Open drug page | |||||
ROS1 inhibitor |
Phase 3 | 31 Oct 2027Phase 3 trial completes | |||
| Next date | 31 Oct 2027 · Phase 3 trial completes | ||||
| Open drug page | |||||
EGFR inhibitor (third generation) |
Phase 3 | 31 Oct 2027Phase 3 trial completes | |||
| Next date | 31 Oct 2027 · Phase 3 trial completes | ||||
| Also tested for | EGFR Activating Mutation, MET Positive | ||||
| Open drug page | |||||
PD-1 antibody |
AbbVie · Public ABBV |
Phase 2/3 | Nov 2027Phase 1/2 trial completes | ||
| Next date | Nov 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Cancer, Advanced Solid Tumors and 9 more | ||||
| Open drug page | |||||
Monoclonal antibody |
AbbVie · Public ABBV |
Phase 3 | Nov 2027Phase 1/2 trial completes | ||
| How it works | An antibody | ||||
| Next date | Nov 2027 · Phase 1/2 trial completes | ||||
| Also tested for | c-MET, Head and Neck Squamous Cell Carcinoma and 8 more | ||||
| Open drug page | |||||
EGFR inhibitor |
Phase 3 | 1 Dec 2027Phase 2 trial completes | |||
| Next date | 1 Dec 2027 · Phase 2 trial completes | ||||
| Also tested for | NSCLC, EGFR Activating Mutation and 1 more | ||||
| Open drug page | |||||
TIGIT antibody |
Arcus Biosciences +1 · Public GILD |
Phase 3 | Dec 2027Phase 2 trial completes | ||
| Next date | Dec 2027 · Phase 2 trial completes | ||||
| Also tested for | Lung Cancer | ||||
| Open drug page | |||||
KRAS G12C inhibitor |
Phase 3 | 31 Dec 2027Phase 3 trial completes | |||
| Next date | 31 Dec 2027 · Phase 3 trial completes | ||||
| Open drug page | |||||
ALK inhibitor |
Phase 3 | Dec 2027Phase 1/2 trial completes | |||
| Next date | Dec 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Locally Advanced Solid Tumor, Metastatic Solid Tumor and 1 more | ||||
| Open drug page | |||||
PD-1/VEGF bispecific antibody |
RemeGen +1 · Public 9995.HK · ABBV |
Phase 3 | 31 Dec 2027Phase 3 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | 31 Dec 2027 · Phase 3 trial completes | ||||
| Also tested for | Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or Cytology | ||||
| Open drug page | |||||
— |
Hengrui · Public 600276.SS |
Phase 3 | Dec 2027Phase 1/2 trial completes | ||
| Next date | Dec 2027 · Phase 1/2 trial completes | ||||
| Open drug page | |||||
Monoclonal antibody |
Gilead (Kite) · Public GILD |
Phase 3 | Dec 2027Phase 2 trial completes | ||
| How it works | An antibody | ||||
| Next date | Dec 2027 · Phase 2 trial completes | ||||
| Also tested for | Lung Cancer | ||||
| Open drug page | |||||
KRAS G12C inhibitor |
Merck & Co. · Public MRK |
Phase 3 | 24 Jan 2028Phase 3 trial completes | ||
| Next date | 24 Jan 2028 · Phase 3 trial completes | ||||
| Also tested for | Malignant Neoplasm, Lung Neoplasm Malignant | ||||
| Open drug page | |||||
EGFR inhibitor (third generation) |
Phase 3 | 1 Feb 2028Phase 3 trial completes | |||
| Next date | 1 Feb 2028 · Phase 3 trial completes | ||||
| Open drug page | |||||
C-Met-targeted antibody-drug conjugate |
AbbVie · Public ABBV |
Phase 3 | Feb 2028Phase 2 trial completes | ||
| Next date | Feb 2028 · Phase 2 trial completes | ||||
| Also tested for | c-MET | ||||
| Open drug page | |||||
PD-L1-targeted antibody-drug conjugate |
Pfizer · Public PFE |
Phase 3 | 10 Mar 2028Phase 3 trial completes | ||
| Next date | 10 Mar 2028 · Phase 3 trial completes | ||||
| Also tested for | Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma and 6 more | ||||
| Open drug page | |||||
PD-L1/VEGF-A bispecific antibody |
BioNTech +1 · Public BNTX · BMY |
Phase 3 | 15 Mar 2028Phase 2 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | 15 Mar 2028 · Phase 2 trial completes | ||||
| Also tested for | Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma and 9 more | ||||
| Open drug page | |||||
— |
Phase 3 | 30 Mar 2028Phase 2 trial completes | |||
| Next date | 30 Mar 2028 · Phase 2 trial completes | ||||
| Also tested for | Advanced Solid Tumors, Colorectal Cancer | ||||
| Open drug page | |||||
PD-L1 antibody fused to a VEGFR1 domain (PD-L1/VEGF) |
Huahai Pharmaceutical (Huaota) · Public 600521.SS |
Phase 3 | 10 Apr 2028Phase 3 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | 10 Apr 2028 · Phase 3 trial completes | ||||
| Also tested for | Advanced Endometrial Cancer | ||||
| Open drug page | |||||
— |
Henlius · Public 2696.HK |
Phase 2/3 | 20 Apr 2028Phase 2 trial completes | ||
| Next date | 20 Apr 2028 · Phase 2 trial completes | ||||
| Also tested for | Solid Tumor Cancer | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Phase 3 | 30 Apr 2028Phase 3 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 30 Apr 2028 · Phase 3 trial completes | ||||
| Also tested for | EGFR Sensitive Mutation, Adjuvant Therapy and 3 more | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Phase 3 | 30 Apr 2028Phase 3 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 30 Apr 2028 · Phase 3 trial completes | ||||
| Also tested for | EGFR Sensitive Mutation, Adjuvant Therapy | ||||
| Open drug page | |||||
— |
Phase 3 | 1 May 2028Phase 3 trial completes | |||
| Next date | 1 May 2028 · Phase 3 trial completes | ||||
| Open drug page | |||||
— |
Hengrui · Public 600276.SS |
Phase 3 | May 2028Phase 3 trial completes | ||
| Next date | May 2028 · Phase 3 trial completes | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Phase 3 | Jun 2028Phase 1/2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | Jun 2028 · Phase 1/2 trial completes | ||||
| Open drug page | |||||
PD-1/VEGF bispecific antibody |
Pfizer +1 · Public PFE · 1530.HK |
Phase 3 | 29 Jul 2028Phase 2 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | 29 Jul 2028 · Phase 2 trial completes | ||||
| Also tested for | Lung Cancer, Carcinoma and 3 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 2/3 | 5 Aug 2028Phase 2/3 trial completes | |||
| How it works | An antibody | ||||
| Next date | 5 Aug 2028 · Phase 2/3 trial completes | ||||
| Open drug page | |||||
EGFR inhibitor (fourth generation, for the C797S mutation) |
Phase 3 | 31 Aug 2028Phase 3 trial completes | |||
| Next date | 31 Aug 2028 · Phase 3 trial completes | ||||
| Also tested for | Lung Cancer, NSCLC | ||||
| Open drug page | |||||
Integrin beta-6-targeted antibody-drug conjugate |
Pfizer · Public PFE |
Phase 3 | 5 Sep 2028Phase 3 trial completes | ||
| Next date | 5 Sep 2028 · Phase 3 trial completes | ||||
| Also tested for | Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms and 9 more | ||||
| Open drug page | |||||
— |
Phase 3 | Sep 2028Phase 3 trial completes | |||
| Next date | Sep 2028 · Phase 3 trial completes | ||||
| Also tested for | NSCLC | ||||
| Open drug page | |||||
IL-15 receptor agonist |
Phase 3 | Sep 2028Phase 3 trial completes | |||
| Next date | Sep 2028 · Phase 3 trial completes | ||||
| Also tested for | Small Cell Lung Cancer, Urothelial Carcinoma and 10 more | ||||
| Open drug page | |||||
— |
Phase 3 | 31 Oct 2028Phase 2/3 trial completes | |||
| Next date | 31 Oct 2028 · Phase 2/3 trial completes | ||||
| Also tested for | Metastatic Lung Cancer, Advanced Cancer and 2 more | ||||
| Open drug page | |||||
EGFR inhibitor (third generation) |
Phase 3 | 31 Oct 2028Phase 1 trial completes | |||
| Next date | 31 Oct 2028 · Phase 1 trial completes | ||||
| Also tested for | Lung Cancer | ||||
| Open drug page | |||||
PD-1 antibody |
Hengrui · Public 600276.SS |
Phase 2/3 | Oct 2028Phase 2/3 trial completes | ||
| Next date | Oct 2028 · Phase 2/3 trial completes | ||||
| Open drug page | |||||
— |
Sinocelltech · Public 688520.SS |
Phase 2/3 | Oct 2028Phase 2 trial completes | ||
| Next date | Oct 2028 · Phase 2 trial completes | ||||
| Open drug page | |||||
— |
Bristol Myers Squibb · Public BMY |
Phase 2/3 | 29 Dec 2028Phase 2 trial completes | ||
| Next date | 29 Dec 2028 · Phase 2 trial completes | ||||
| Also tested for | Mesothelioma, Malignant Peripheral Nerve Sheath Tumors and 3 more | ||||
| Open drug page | |||||
ROS1/TRK inhibitor |
Nuvation Bio +1 · Public 1801.HK |
Phase 3 | Jan 2029Phase 3 trial completes | ||
| Next date | Jan 2029 · Phase 3 trial completes | ||||
| Open drug page | |||||
B7-H3-targeted antibody-drug conjugate |
Phase 3 | Mar 2029Phase 3 trial completes | |||
| Next date | Mar 2029 · Phase 3 trial completes | ||||
| Also tested for | Lung Squamous Cell Carcinoma | ||||
| Open drug page | |||||
— |
Phase 3 | Apr 2029Phase 3 trial completes | |||
| Next date | Apr 2029 · Phase 3 trial completes | ||||
| Also tested for | NSCLC | ||||
| Open drug page | |||||
Tubulin-binding agent |
Phase 3 | 1 Jun 2029Phase 3 trial completes | |||
| Next date | 1 Jun 2029 · Phase 3 trial completes | ||||
| Also tested for | Non-squamous Non-Small Cell Lung Cance | ||||
| Open drug page | |||||
Personalised mRNA cancer vaccine |
Merck & Co. +1 · Public MRK · MRNA |
Phase 3 | 2 Jul 2029Phase 2 trial completes | ||
| Next date | 2 Jul 2029 · Phase 2 trial completes | ||||
| Open drug page | |||||
— |
AbbVie · Public ABBV |
Phase 3 | Dec 2029Phase 3 trial completes | ||
| Next date | Dec 2029 · Phase 3 trial completes | ||||
| Open drug page | |||||
EGFR antibody |
Henlius · Public 2696.HK |
Phase 2/3 | 15 Jan 2030Phase 2/3 trial completes | ||
| Next date | 15 Jan 2030 · Phase 2/3 trial completes | ||||
| Also tested for | Squamous NSCLC | ||||
| Open drug page | |||||
— |
Phase 3 | 31 May 2030Phase 3 trial completes | |||
| Next date | 31 May 2030 · Phase 3 trial completes | ||||
| Also tested for | Advanced Solid Tumors, Colorectal Cancer | ||||
| Open drug page | |||||
KRAS G12D degrader |
Phase 3 | 30 Jun 2030Phase 3 trial completes | |||
| Next date | 30 Jun 2030 · Phase 3 trial completes | ||||
| Open drug page | |||||
Monoclonal antibody |
Bristol Myers Squibb · Public BMY |
Phase 3 | 30 Jul 2030Phase 3 trial completes | ||
| How it works | An antibody | ||||
| Next date | 30 Jul 2030 · Phase 3 trial completes | ||||
| Open drug page | |||||
PD-L1/VEGF bispecific antibody |
Henlius · Public 2696.HK |
Phase 2/3 | 30 Dec 2030Phase 2/3 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | 30 Dec 2030 · Phase 2/3 trial completes | ||||
| Also tested for | Advanced/Metastatic Solid Tumors, NSCLC | ||||
| Open drug page | |||||
Monoclonal antibody |
Hengrui · Public 600276.SS |
Phase 3 | Feb 2031Phase 3 trial completes | ||
| How it works | An antibody | ||||
| Next date | Feb 2031 · Phase 3 trial completes | ||||
| Open drug page | |||||
Gene therapy: adenovirus carrying a herpes virus enzyme gene, given with a prodrug |
Phase 3 | 22 Oct 2031Phase 3 trial completes | |||
| Next date | 22 Oct 2031 · Phase 3 trial completes | ||||
| Open drug page | |||||
GARP/TGF-beta antibody |
AbbVie · Public ABBV |
Phase 2/3 | Oct 2031Phase 2/3 trial completes | ||
| Next date | Oct 2031 · Phase 2/3 trial completes | ||||
| Open drug page | |||||
Kinase inhibitor |
Eli Lilly · Public LLY |
Phase 3 | — | ||
| How it works | Blocks a kinase | ||||
| Also tested for | Breast Cancer | ||||
| Open drug page | |||||
TIGIT antibody |
GSK +1 |
Phase 3 | — | ||
| Open drug page | |||||
PD-1/CTLA-4 bispecific antibody |
Akeso · Public 9926.HK |
Phase 3 | — | ||
| How it works | A cancer drug that hits three targets | ||||
| Open drug page | |||||
ATR inhibitor |
AstraZeneca · Public AZN |
Phase 3 | — | ||
| Also tested for | Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 2/3 | — | |||
| How it works | An antibody | ||||
| Open drug page | |||||
— |
Phase 3 | — | |||
| Open drug page | |||||
ALK/ROS1 inhibitor |
Phase 3 | — | |||
| Open drug page | |||||
PD-1 antibody |
Phase 3 | — | |||
| Open drug page | |||||
ALK inhibitor |
Xcovery +1 |
Phase 3 | — | ||
| Open drug page | |||||
— |
Phase 3 | — | |||
| Open drug page | |||||
— |
Phase 3 | — | |||
| Also tested for | Lung Cancer | ||||
| Open drug page | |||||
MB12not checked |
— |
Phase 3 | — | ||
| Open drug page | |||||
EGFR inhibitor |
Phase 3 | — | |||
| Open drug page | |||||
VEGFR2 antibody |
Eli Lilly · Public LLY |
Phase 3 | — | ||
| Open drug page | |||||
— |
Phase 3 | — | |||
| Open drug page | |||||
MEK inhibitor |
AstraZeneca · Public AZN |
Phase 3 | — | ||
| Open drug page | |||||
PD-1 antibody |
Innovent · Public 1801.HK |
Phase 3 | — | ||
| Open drug page | |||||
CTLA-4 antibody |
AstraZeneca · Public AZN |
Phase 3 | — | ||
| How it works | A cancer drug that hits three targets | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Covers
- 666 of 683 active trials the registry tags as Non-Small-Cell Lung Carcinoma (98%) · Breakdown
- Matches
- Conditions, trial titles, drug names and codes, other names, how it works and company.
- Checked
- 144 of 149 drugs. The other 5 are marked “not checked” in the list. How we check
- Sources
- ClinicalTrials.gov updated 16 Nov 2026 · openFDA updated 13 Nov 2026 · Company press releases
Ask your AI about this landscape. Connect it once, then ask in plain English.
Connect your AI
Which Phase 3 lung cancer trials read out in the next six months?Which should we check next?
Need a landscape built for you? Talk to us.
